Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;3(7):e2015100.
doi: 10.1001/jamanetworkopen.2020.15100.

Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic

Ramez Kouzy  1 , Joseph Abi Jaoude  1 , Carolina J Garcia Garcia  1 , Molly B El Alam  1 , Cullen M Taniguchi  1 , Ethan B Ludmir  1
Affiliations

Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic

Ramez Kouzy et al. JAMA Netw Open. .

Abstract

This systematic review examines current randomized clinical trials of therapeutic agents to treat coronavirus disease 2019 (COVID-19).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Ms Garcia Garcia reported receiving support from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) (award number F31DK121384). Dr Taniguchi reported receiving supported from the NIH (award R01CA227517-01A1), Cancer Prevention & Research Institute of Texas (grant RR140012), V Foundation (grant V2015-22), the Kimmel Foundation, Sabin Family Foundation Fellowship, and the McNair Foundation and reported being a member of the clinical advisory board of Accuray outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Flowchart of Screening, Eligibility, and Inclusion of Randomized Clinical Trials for Coronavirus Disease 2019 (COVID-19)
See this image and copyright information in PMC

References

    1. Goodman JL, Borio L. Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis. JAMA. 2020;323(19):1899-1900. doi:10.1001/jama.2020.6434 - DOI - PubMed
    1. Kalil AC. Treating COVID-19: off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020;323(19):1897-1898. doi:10.1001/jama.2020.4742 - DOI - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269. doi:10.7326/0003-4819-151-4-200908180-00135 - DOI - PubMed
    1. Prasad V, Booth CM. Multiplicity in oncology randomised controlled trials: a threat to medical evidence? Lancet Oncol. 2019;20(12):1638-1640. doi:10.1016/S1470-2045(19)30744-2 - DOI - PubMed
    1. Reuters China trial of Gilead’s potential coronavirus treatment suspended. Published April 15, 2020. Accessed April 16, 2020. https://www.reuters.com/article/us-health-coronavirus-gilead-remdesivir/...

Publication types

MeSH terms